Dr. Hayder Saeed of the Moffitt Cancer Center recently presented key insights from his presentation at the 2024 OncLive® conference on the use of polatuzumab vedotin-piiq (Polivy) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) for adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
The presentation, titled ‘Pola for Everyone,’ focused on the approval of polatuzumab vedotin by the FDA in August 2023 for use with R-CHP therapy in patients with previously untreated DLBCL. This approval was based on the results of the phase 3 POLARIX trial, which showed a 2-year progression-free survival rate of 76.7% in patients who received pola-R-CHP.
Dr. Saeed emphasized the significance of substituting vincristine chemotherapy with polatuzumab vedotin in the R-CHP regimen, as demonstrated by the POLARIX study. This marked a substantial advancement in treatment standards for DLBCL patients, sparking important discussions within the medical community.
While the study’s findings are promising, Dr. Saeed noted that they may not apply to all newly diagnosed DLBCL patients. Understanding the nuances of subgroup analyses and applying these outcomes appropriately is crucial for effective disease management, he concluded.
